Pharmaceutical - Anti-virals

Filter

Current filters:

Anti-virals

Popular Filters

76 to 100 of 309 results

BiondVax’ universal flu vaccine matches all six potentially pandemic flu strains in the world

21-01-2014

BiondVax Pharmaceuticals, an Israeli company developing a universal flu vaccine, says it has completed…

Anti-viralsBiondVaxPharmaceuticalResearchVaccines

New drug combo cures toughest cases of hepatitis C, hints to future injection-free therapies

16-01-2014

Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans…

Anti-viralsBristol-Myers SquibbdaclatasvirGilead SciencesPharmaceuticalResearchsofosbuvir

Tivicay set to become leading HIV treatment by 2016

Tivicay set to become leading HIV treatment by 2016

15-01-2014

Antiretroviral drug Tivicay (dolutegravir) is set to become the leading integrase inhibitor for the treatment…

Anti-viralsAsia-PacificEuropeIsentressJanssenMarkets & MarketingMerck & CoPharmaceuticalPrezistaTivicayUSAViiV Healthcare

UK MPs express concerns on clinical trial data transparency and Tamiflu stockpiling

UK MPs express concerns on clinical trial data transparency and Tamiflu stockpiling

06-01-2014

The UK House of Commons Public Accounts Committee is calling for all data on drugs being prescribed in…

Anti-viralsNorthern EuropePharmaceuticalRegulationResearchRocheTamifluUK

Leading Chinese hepatitis B vaccine makers stop production; Pfizer drug import halted

03-01-2014

China’s Food and Drug Administration announced on January 2 that the country’s three leading manufacturers…

Anti-viralsAntibiotics and Infectious diseasesAsia-PacificBioKangtaiChinaFluconazolePfizerPharmaceuticalRegulationVaccines

Nigerian activists move to stop supply of sub-standard HIV/AIDS drugs

03-01-2014

Treatment Action Movement (TAM), a coalition of HIV treatment activists in Nigeria, in collaboration…

Anti-viralsPharmaceuticalRegulationRest of the WorldTYONEXTyonex Nigeria

China bans BioKangtai hepatitis B vaccine

26-12-2013

Chinese authorities on Friday issued a circular to ban the use of the recombinant hepatitis B vaccine…

Anti-viralsAsia-PacificBioKangtaiChinaHealthcarePharmaceuticalRegulationVaccines

Ukraine government introduces compulsory licensing for pharma products

Ukraine government introduces compulsory licensing for pharma products

23-12-2013

Leading global pharmaceutical producers may suffer significant losses in Ukraine, as the country’s…

Anti-viralsAntibiotics and Infectious diseasesEastern EuropeLicensingOncologyPatentsPharmaceuticalUkraine

Boehringer Ingelheim’s faldaprevir effective even in hep C patients with common drug-resistant viral variant

Boehringer Ingelheim’s faldaprevir effective even in hep C patients with common drug-resistant viral variant

17-12-2013

New data show that family-owned German drug major Boehringer Ingelheim’s second-generation protease…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalResearch

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

AbbVie reports 96% response in Phase III hepatitis C study

AbbVie reports 96% response in Phase III hepatitis C study

10-12-2013

US drugmaker AbbVie (NYSE: ABBV)has released Phase III results for the investigational three direct-acting-antiviral…

AbbVieAnti-viralsAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

Catalyst-rich period ahead for key trial results from BioLineRx

09-12-2013

Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…

Anti-viralsBioLineRxBL-1040BL-8020BL-8040Cardio-vascularFinancialOncologyPharmaceuticalResearch

Revised clinical practice guidelines for management of hepatitis C virus infection from EASL

09-12-2013

The European Association for the Study of the Liver has today published its revised Clinical Practice…

Anti-viralsEuropePharmaceuticalRegulation

AstraZeneca’s Fluenz Tetra cleared in EU

AstraZeneca’s Fluenz Tetra cleared in EU

06-12-2013

The European Commission has granted Marketing Authorization to Fluenz Tetra, the product’s maker Anglo-Swedish…

Anti-viralsAstraZenecaEuropeFluenz TetraPharmaceuticalRegulationVaccines

IFPMA and the Global Fund collaborate to help protect patients from fake medicines

05-12-2013

The International Federation of Pharmaceutical Manufacturers and Associations and the Global Fund to…

Anti-viralsAntibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceuticalRegulationTropical diseases

Teva unveils new pipeline assets from its 2013 NTE program

Teva unveils new pipeline assets from its 2013 NTE program

05-12-2013

Best known as the world’s biggest generic drugmaker, Israel’s Teva Pharmaceutical Industries yesterday…

Anti-viralsCopaxoneNeurologicalPharmaceuticalResearchTeva Pharmaceutical Industries

Global Fund-proposed shake-up to drug pricing framework risks middle-income countries paying more, says MSF

Global Fund-proposed shake-up to drug pricing framework risks middle-income countries paying more, says MSF

04-12-2013

Ahead of the Global Fund replenishment conference in Washington DC this week, international medical humanitarian…

Anti-viralsAntibiotics and Infectious diseasesGlobalPharmaceutical

One in five South African health care centers experience ARV stock shortages

29-11-2013

South Africa’s Treatment Action Campaign (TAC) has warned that the country’s HIV treatment program…

Anti-viralsHealthcarePharmaceuticalProductionRest of the WorldSouth Africa

AHF sues Abbott and AbbVie for overcharging on AIDS drug pricing

AHF sues Abbott and AbbVie for overcharging on AIDS drug pricing

28-11-2013

In further legal action against drugmakers allegedly over pricing AIDS drugs in the USA, the AIDS Healthcare…

Abbott LaboratoriesAbbVieAnti-viralsKaletra TabletsLegalNorth AmericaNorvirPharmaceuticalPricing

EMA accelerated assessment for Boehringer hep C candidate faldaprevir

EMA accelerated assessment for Boehringer hep C candidate faldaprevir

27-11-2013

Family-owned German drug major Boehringer Ingelheim says that its application for European marketing…

Anti-viralsBoehringer IngelheimEuropefaldaprevirPharmaceuticalRegulation

J&J’s Invokana approved in Europe and Olysio cleared in USA

J&J’s Invokana approved in Europe and Olysio cleared in USA

25-11-2013

It was a good news day for US health care giant Johnson & Johnson, with two of its Janssen subsidiaries…

Anti-viralsDiabetesEuropeInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaOlysioPharmaceuticalRegulation

76 to 100 of 309 results

Back to top